Introduction
In fetal alloimmune thrombocytopenia fetal platelets are destroyed due to maternal allo-antibodies directed at paternally inherited platelet antigens (human platelet antigens, HPA). Neonates with severe thrombocytopenia suffer from skin and mucous membrane petechiae and, in 10-20% will develop intracranial haemorrhage (1) (2) (3) . Besides the more invasive therapeutic approach of (repeated) intrauterine transfusions (IUT) of compatible platelets maternal i.v. administration of high-dose (non-specific) immunoglobulin G have been used (1, (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . In this retrospective observational study we analyzed fetal and maternal immunoglobulin levels and fetal platelets under such a regime.
Design and methods

Patients
Data from 29 otherwise healthy pregnant women (28 singletons and one twin pregnancy), treated between 1999 and 2005, were analyzed retrospectively, comprising 25 women referred because of previous newborns with fetal alloimmune thrombocytopenia defined as thrombopenia (platelet counts below 100,000x10(9)/L, antibody-coated platelets as measured by a platelet glycoprotein-specific assay) as well as haematoma or skin bleedings at birth; molecular analyses not consistently done) and four women with prior spontaneous abortions, found to carry high titres of platelet antibodies. 25 women had between one and four previous newborns with neonatal alloimmune thrombocytopenia, but none with intracranial haemorrhage. All pregnant women had normal platelet counts, normal IgG levels and no clinical signs or history of bleeding. All parents had been genotyped for HPA.
Serological and molecular testing
From all pregnant women and fetuses EDTA-anticoagulated and native blood samples were obtained for a full blood count including platelets, overall immunoglobulin levels and anti-HPA antibody levels and, at the initial sampling, antigen testing. The paternal genotype was also determined at the beginning of each treatment course.
Platelets were counted using and automated platelet counter (Sysmex model E 5000, Digitana, Hamburg, Germany) and values given as platelets x10(9)/L. In addition, blood smears with Pappenheim staining were performed in each case in order to examine the presence or absence of platelet agglutinates.
At each maternal blood sampling the previously diagnosed maternal HPA antibodies were confirmed by immunofluorescence and monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay (15) . HPA antibodies were considered "high titre" for MAIPA photometric extinction units at 492-690nm from 0.81 -2.0 and medium and weak corresponding with extinctions 0.41 -0.8 and 0.2 -0.4, respectively.
Fetal origin of the intrauterine blood samples were confirmed by measuring mean corpuscular volume (16) and Kleihauer-Betke test (acid elution test (17) ). In addition to serological typing, at each first fetal blood sampling the fetal HPA genotype was determined (18) .
Treatment protocol
Once the diagnosis of fetal alloimmune thrombocytopenia was confirmed by invasive testing, the pregnant women received weekly infusions of intravenous immunoglobulin (Endobulin ! Immuno GmbH, Heidelberg, Germany) at 1g per kg body weight. All cases were managed identically in a specific protocol by one highly No longer than four hours before delivery, which was by caesarean section in all cases, each fetus received one intrauterine platelet transfusion. These transfusions were done with platelets prepared either maternal (n=22) or group O, HPA compatible platelets (n=7). All neonates were examined clinically for isolated or confluent petechiae, haematoma, mucous bleedings, including sonographic examination of the abdomen and brain.
The treatment was performed according to the institutional standard protocols in effect at the time. Informed consent was obtained from all pregnant women, and the study was approved by the Institutional review board.
Platelet preparations for intrauterine transfusions
Maternal and donor platelets were selected and prepared as described previously (19, 20) . Unrelated donors had group 0 red blood cells and were negative for cytomegalovirus antibodies. They were HPA-typed and matched and lacking the antigen corresponding to the individual maternal platelet antibodies as well as platelet, HLA and cytomegalovirus antibodies. The donor platelets were collected using an automated hemapheresis procedure (MCS+, Haemonetics, Braintree, Massachusetts, USA) and leukocyte-depleted (20).
Statistical methods
Individual fetal platelet count courses and maternal and fetal immunoglobulin G levels as well as the ratio between maternal and fetal immunoglobulin levels were first analyzed visually in XY plots over gestation.
For detailed statistical analysis, the maximum likelihood (method was used to estimate maternal and fetal IgG levels and fetal platelet counts longitudinally for gestational ages for which sufficient numbers of cases were present. This method assumes a missing value mechanism ("missing at random") which is independent of the non-measured data instead of simple assumption of non-randomness (21-23).
The missing-at-random method was empirically validated by Cox regression results.
Because fetal platelets counts were not normally distributed, a logarithmic transformation was applied prior to the analysis. All statistical calculations were performed using a commercial statistics package (24) .
Results
Patient characteristics
All women had given birth before (between two and seven times, median three deliveries). 25 women had between one and four previous newborns with neonatal alloimmune thrombocytopenia. Only four of them did not have a previous newborn with neonatal alloimmune thrombocytopenia; these women had between two and four previous pregnancies ending in spontaneous abortions and showed high levels of HPA antibodies.
Maternal antibody specificities were anti-HPA-1a in 25 women, anti-HPA-3a in two and anti-HPA-5b in another two women; the HPA antibodies were directed towards paternally inherited platelet antigens in all cases. Maternal HPA-1a antibodies scores were higher (extinctions mean=1.48; range=1.02-1.93) than HPA-3a (n=2: extinctions 0.65 and 1.0, respectively) and HPA-5b (n=3; extinctions 1.24, 0.5, 1.11, respectively). Maternal HPA antibody levels assessed at almost every fetal blood sampling did not change significantly (p<0.05; Figure S1 ) despite repeated fetal blood samplings.
Clinical courses
Treatment was begun promptly when the patient first presented (between 20 and 33 weeks' gestation, median 27 weeks) and continued to delivery at a median gestational age of 35.3 weeks (range 35.0-37.1).
There were 219 fetal blood samplings in total, between two and 14 fetal blood samplings per fetus (median seven). Only at the final fetal blood sampling each fetus received an intrauterine platelet transfusion which raised the fetal platelet count at delivery to between 40,000 and 376,000 (median 178,000). There were no procedure-related fetal complications. None of the fetuses or neonates had bleeding complications (major or minor) at birth, and there were no fetal or neonatal losses.
No adverse events occurred during or after the immunioglobulin infusions.
Fetal platelet counts
At the time of the first blood sampling, at a mean gestational age of 27.0 weeks (range 20.0-33.0 weeks), the mean fetal platelet count was 56,300 (range 4,000-130,000, median 43,500). The mean minimal fetal platelet count during gestation was 21,500 (range 4,000-60,000, median 19,500). Platelet counts before birth (and before the single intrauterine platelet transfusion immediately before delivery) were on average 31,300 (range 6,000-117,000, median 24,000). Throughout gestation, 17/30 (57%) of the fetuses had minimum intrauterine platelet counts <=20,000. Only four fetuses (13%) had a final platelet count above 50,000 immediately before their predelivery intrauterine platelet transfusion. The individual fetal platelet counts during weekly maternal i.v. immunoglobulin G infusions are shown in figure 1 and the statistical model for these mean fetal platelet counts in figure 2.
There was no consistent increase of fetal platelet counts despite the maternal immunoglobulin G infusions, but a trend towards decreasing fetal platelet counts from 26 to 34 gestational weeks. Longitudinal analysis of the log transformed data confirmed that there was a decrease in fetal platelets between the first measurements at 26 weeks and the last at 34 weeks despite maternal immunoglobulin G infusions (Figure 2 ; numerical data of statistical analysis of fetal platelet counts between 26 and 34 weeks in Table S3 ).
Maternal and fetal IgG and HPA antibody levels
Both fetal and maternal immunoglobulin G levels increased in women receiving weekly maternal intravenous immunoglobulin infusion for fetal alloimmune thrombocytopenia (Figures S2 and S3 and Tables S1 and S2 ). There was no significant change in maternal (indirect MAIPA, Figure S4 ) and fetal HPA antibody levels (data not shown). The ratio between maternal and fetal immunoglobulin levels remained constant in the majority of mother-fetus pairs with maternal levels about three times as high as fetal levels (data not shown). Berkowitz (9) reported data from a multi-centre trial of 42 institutions, contributing a total of 79 fetuses, who were treated with maternal i.v. immunoglobulin G and, some, also with maternally administered steroids. In the "standard" and "high risk"
Discussion
subgroups "(platelets <20,000 or affected older sibling) initial platelet counts (at on average 24 weeks) were 56,300 and 8,500, respectively. Some, but not all fetuses had follow-up platelet counts, and the actual number of intrauterine transfusions below 50,000/ul platelets as per protocol was not given. 
Limitations of the current study
We did not study the predictive value of previous affected pregnancies, their severity or time of onset of disease or the association with antibody levels and the degree of fetal thrombocytopenia. Nor was the therapeutic effect of steroids, alone or in combination with i.v. immunoglobulin G, part of our study. These aspects have been used to stratify cases by risk and to tailor prenatal treatment (9, 13, 34, 35) . To-date there is no standard for the treatment of fetal alloimmune thrombocytopenia (26) , but a tendency to avoid serial fetal blood samplings and to follow these high-risk cases in specialized centres (36) . A recent study showed the value of a standardized assessment of maternal antibody levels at least for the prediction of the severity of fetal alloimmune thrombocytopenia which may ultimately aid in selecting and timing the appropriate therapy (35) .
Published evidence suggests that maternally infused immunoglobulin may be effective at least in some cases, but the largest multi-centre studies, aiming to reduce 
